Treating Medicaid Patients with Hepatitis C: Clinical and Economic Impact

American Journal of Managed Care

Volumn 23, Issue 2, 2017, Pages 107-112

  Younossi, Zobair ^a,b   Gordon, Stuart C ^c   Ahmed, Aijaz ^d   Dieterich, Douglas ^e   Saab, Sammy ^f   Beckerman, Rachel ^g  

^a INOVA FAIRFAX HOSPITAL   (United States)

^b BETTY AND GUY BEATTY CENTER FOR INTEGRATED RESEARCH   (United States)

^c HENRY FORD HOSPITAL   (United States)

^d STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^f UNIVERSITY OF CALIFORNIA   (United States)

^g Maple Health Group LLC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LEDIPASVIR PLUS SOFOSBUVIR; ANTIVIRUS AGENT; BENZIMIDAZOLE DERIVATIVE; FLUORENE DERIVATIVE; LEDIPASVIR, SOFOSBUVIR DRUG COMBINATION; URIDINE PHOSPHATE;

ARTICLE; CHRONIC HEPATITIS C; COHORT ANALYSIS; COST CONTROL; COST EFFECTIVENESS ANALYSIS; DECOMPENSATED LIVER CIRRHOSIS; ECONOMIC ASPECT; FOLLOW UP; HEALTH CARE COST; HOSPITALIZATION COST; HUMAN; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER FIBROSIS; LIVER GRAFT; MEDICAID; MEDICARE; OUTPATIENT CARE; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; SUSTAINED VIROLOGIC RESPONSE; VIRUS LOAD; AGED; ANALOGS AND DERIVATIVES; ECONOMICS; FEMALE; MALE; MARKOV CHAIN; REIMBURSEMENT; TREATMENT OUTCOME; UNITED STATES;

AGED; ANTIVIRAL AGENTS; BENZIMIDAZOLES; FEMALE; FLUORENES; HEPATITIS C, CHRONIC; HUMANS; INSURANCE, HEALTH, REIMBURSEMENT; MALE; MARKOV CHAINS; MEDICAID; QUALITY-ADJUSTED LIFE YEARS; TREATMENT OUTCOME; UNITED STATES; URIDINE MONOPHOSPHATE; VIRAL LOAD;

EID: 85015359559     PISSN: 10880224     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. Edlin BR, Eckhardt BJ, Shu MA, Holmberg SD, Swan T. Toward a more accurate estimate of the prevalence of hepatitis C in the United States. Hepatology. 2015;62(5):1353-1363. doi: 10.1002/hep.27978.
2. Cacoub P, Gragnani L, Comarmond C, Zignego AL. Extrahepatic manifestations of chronic hepatitis C virus infection. Dig Liver Dis. 2014;46(suppl 5):S165-S173. doi: 10.1016/j.dld.2014.10.005.
3. Younossi Z, Henry L. Systematic review: patient-reported outcomes in chronic hepatitis C-the impact of liver disease and new treatment regimens. Aliment Pharmacol Ther. 2015;41(6):497-520. doi: 10.1111/apt.13090.
4. Menzin J, White LA, Nichols C, Deniz B. The economic burden of advanced liver disease among patients with hepatitis C virus: a large state Medicaid perspective. BMC Health Serv Res. 2012;12:459. doi: 10.1186/1472-6963-12-459.
5. Manne V, Sassi K, Allen R, Saab S. Hepatitis C and work impairment: a review of current literature. J Clin Gastroenterol. 2014;48(7):595-599. doi: 10.1097/MCG.0000000000000080.
6. Heim MH. 25 years of interferon-based treatment of chronic hepatitis C: an epoch coming to an end. Nat Rev Immunol. 2013;13(7):535-542. doi: 10.1038/nri3463.
7. Smith BD, Yartel AK, Krauskopf K, et al. Hepatitis C virus antibody positivity and predictors among previously undiagnosed adult primary care outpatients: cross-sectional analysis of a multisite retrospective cohort study. Clin Infect Dis. 2015;60(8):1145-1152. doi: 10.1093/cid/civ002.
8. Assoumou SA, Huang W, Horsburgh CR Jr, Drainoni ML, Linas BP. Relationship between hepatitis C clinical testing site and linkage to care. Open Forum Infect Dis. 2014;1(1):ofu009. doi: 10.1093/ofid/ofu009.
9. Reau N. HCV testing and linkage to care: expanding access. Clin Liver Dis. 2014;4(2):31-34. doi/10.1002/cld.376.
10. Falck-Ytter Y, Kale H, Mullen KD, Sarbah SA, Sorescu L, McCullough AJ. Surprisingly small effect of antiviral treatment in patients with hepatitis C. Ann Intern Med. 2002;136(4):288-292.
11. Stepanova M, Younossi ZM. Interferon-free regimens for chronic hepatitis c: barriers due to treatment candidacy and insurance coverage. Dig Dis Sci. 2015;60(11):3248-3251. doi: 10.1007/s10620-015-3709-6.
12. Wise M, Bialek S, Finelli L, Bell BP, Sorvillo F. Changing trends in hepatitis C-related mortality in the United States, 1995-2004. Hepatology. 2008;47(4):1128-1135. doi: 10.1002/hep.22165.
13. Xu F, Tong X, Leidner AJ. Hospitalizations and costs associated with hepatitis C and advanced liver disease continue to increase. Health Aff (Millwood). 2014;33(10):1728-1735. doi: 10.1377/hlthaff.2014.0096.
14. Kanwal F, Hoang T, Kramer JR, et al. Increasing prevalence of HCC and cirrhosis in patients with chronic hepatitis C virus infection. Gastroenterology. 2011;140(4):1182-1188. doi: 10.1053/j.gastro.2010.12.032.
15. Ferro C, Blumen HE, Johnson RL. The burden of hepatitis C virus disease in commercial and managed Medicaid populations. Milliman website. www.us.milliman.com/insight/2015/The-burden-of-hepatitis-Cvirus-disease-in-commercial-and-managed-Medicaid-populations/. Published September 24, 2015. Accessed January 24, 2016.
16. Younossi ZM, Boparai N, Price LL, Kiwi ML, McCormick M, Guyatt G. Health-related quality of life in chronic liver disease: the impact of type and severity of disease. Am J Gastroenterol. 2001;96(7):2199-2205.
17. Oliva-Moreno J, Peña-Longobardo LM, Alonso S, et al. Labour productivity losses caused by premature death associated with hepatitis C in Spain. Eur J Gastroenterol Hepatol. 2015;27(6):631-637. doi: 10.1097/MEG.0000000000000336.
18. El Khoury AC, Wallace C, Klimack WK, Razavi H. Economic burden of hepatitis C-associated diseases: Europe, Asia Pacific, and the Americas. J Med Econ. 2012;15(5):887-896. doi: 10.3111/13696998.2012.681332.
19. Leidner AJ, Chesson HW, Xu F, Ward JW, Spradling PR, Holmberg SD. Cost-effectiveness of hepatitis C treatment for patients in early stages of liver disease. Hepatology. 2015;61(6):1860-1869. doi: 10.1002/hep.27736.
20. Martin NK, Vickerman P, Dore GJ, et al. Prioritization of HCV treatment in the direct-acting antiviral era: an economic evaluation. J Hepatol. 2016;61(1):17-25. doi: 10.1016/j.jhep.2016.02.007.
21. Younossi ZM, Park H, Saab S, Ahmed A, Dieterich D, Gordon SC. Cost-effectiveness of all-oral ledipasvir/sofosbuvir regimens in patients with chronic hepatitis C virus genotype 1 infection. Aliment Pharmacol Ther. 2015;41(6):544-563. doi: 10.1111/apt.13081.